Naoki Takezako
Japan Association for Development of Community Medicine(JP)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research, Peptidase Inhibition and Analysis, Cancer Treatment and Pharmacology
Most-Cited Works
- → Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma(2018)530 cited
- → Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial(2019)241 cited
- → Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study(2020)233 cited
- → Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX(2018)209 cited
- Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.(2000)
- → Prophylactic action of oral fluconazole against fungal infection in neutropenic patients(2000)123 cited
- → Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma(2001)123 cited
- → Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial(2022)108 cited
- → Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial(2020)101 cited
- → ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells(2009)78 cited